SciELO - Brasil - Treatment of advanced melanoma - A changing landscape Treatment of advanced melanoma - A changing landscape
Health-related quality of life results from the phase III CheckMate 067 study - ScienceDirect
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
CheckMate 067: Dual Checkpoint Blockade Proves Effective in Advanced Melanoma - The ASCO Post
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials - The Lancet Oncology
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
Perspective on the Use of Nivolumab Combined with Ipilimumab For Advanced Melanoma | SCF - Skin Cancer Foundation Provider
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
Checkmate 067 and 238 Melanoma Efficacy | OPDIVO® (nivolumab), OPDIVO + YERVOY® (ipilimumab)
Clinical utility of nivolumab in the treatment of advanced melanoma | TCRM
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial -
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Six-and-a-Half-Year Outcomes for Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Continue to Demonstrate Durable Long-Term Survival Benefits in Patients with Advanced Melanoma - AIM at Melanoma Foundation
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
![PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/05d8ec52e94baed4fc4663945cff5b66471673c8/4-Figure3-1.png "PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar")
PDF] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada | Semantic Scholar
Melanoma - ASCO 2021 Skin Cancer Highlights - Skin Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
The Lancet Oncology on Twitter: "Presented at #ESMO2018 @myESMO: #Nivolumab plus #ipilimumab or nivolumab alone versus ipilimumab alone in advanced #melanoma (#CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma | NEJM
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial - The Lancet Oncology
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab-Containing Regimen in Advanced Melanoma
NEJM on Twitter: "Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (CheckMate 067) https://t.co/0pcpqYVD59 #ESMO17 https://t.co/EpX5KyPgOS" / Twitter
